

Watch: Neola Medical CEO discusses FDA Breakthrough Device Designation

Neola Medical's CEO Hanna Sjöström has been interviewed by Redeye Equity Research Analyst Oscar Bergman following the FDA's decision to grant Neola® Breakthrough Device Designation.

In the interview, Hanna Sjöström discusses the process leading to the designation, what it means for Neola Medical's US regulatory pathway, and the key milestones ahead.

The designation provides for more frequent and interactive communication with the FDA, as well as prioritized review of future regulatory submissions. It represents an important external validation of the clinical need and the potential of Neola® to support earlier detection of potentially life-threatening lung collapse in preterm infants.

Watch the interview here:

<https://player.vimeo.com/video/1224613918>

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

David Folkesson, CFO

email: david.folkesson@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung collapse in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on near-infrared light measurements in the lungs. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

[Watch: Neola Medical CEO discusses FDA Breakthrough Device Designation](#)